Cargando…

The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes

OBJECTIVE: Exenatide has been demonstrated beneficial effects on patients with type 2 diabetes mellitus (T2DM) regarding lipid metabolism. However, the potential mechanism remains unclear. We used a lipidomic approach to evaluate lipid changes in response to treatment with exenatide in T2DM patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lin, Hu, Yanjin, An, Yu, Wang, Qiu, Liu, Jia, Wang, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009038/ https://www.ncbi.nlm.nih.gov/pubmed/35432194 http://dx.doi.org/10.3389/fendo.2022.677202

Ejemplares similares

Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus
por: Song, Jinfang, et al.
Publicado: (2022)

Serum lipidomics profiles reveal potential lipid markers for prediabetes and type 2 diabetes in patients from multiple communities
por: Xuan, Qiuhui, et al.
Publicado: (2022)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study
por: Hu, Yanjin, et al.
Publicado: (2018)

Lipidomics Reveals Serum Specific Lipid Alterations in Diabetic Nephropathy
por: Xu, Tingting, et al.
Publicado: (2021)

The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study
por: Li, Boyu, et al.
Publicado: (2020)

Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart
por: Ding, Wei, et al.
Publicado: (2019)

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
por: Pencek, R, et al.
Publicado: (2012)

Comprehensive Lipidome Profiling of the Kidney in Early-Stage Diabetic Nephropathy
por: Hou, Biyu, et al.
Publicado: (2020)

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus
por: Pereira, Marie, et al.
Publicado: (2017)

Follicular fluid lipidomic profiling reveals potential biomarkers of polycystic ovary syndrome: A pilot study
por: Ding, Ying, et al.
Publicado: (2022)

Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway
por: Liu, Yu, et al.
Publicado: (2021)

Commentary: Comprehensive lipidome profiling of the kidney in early-stage diabetic nephropathy
por: Iizuka, Katsumi
Publicado: (2022)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
por: Tobin, G S, et al.
Publicado: (2012)

Seminal Plasma Lipidomics Profiling to Identify Signatures of Kallmann Syndrome
por: Li, Xiaogang, et al.
Publicado: (2021)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
por: Bai, Chuanmin, et al.
Publicado: (2022)

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
por: Dawson, Alison J., et al.
Publicado: (2019)

Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells
por: Wang, Yao, et al.
Publicado: (2021)

DNA methylation profiling reveals novel pathway implicated in cardiovascular diseases of diabetes
por: Hu, Shengqing, et al.
Publicado: (2023)

The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
por: Mansur, Sity Aishah, et al.
Publicado: (2019)

Lipidomics Profiling Reveals Serum Phospholipids Associated with Albuminuria in Early Type 2 Diabetic Kidney Disease
por: Ye, Shu, et al.
Publicado: (2023)

Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes
por: Ding, Jia-Tong, et al.
Publicado: (2023)

Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

Lipidomics profiles of human spermatozoa: insights into capacitation and acrosome reaction using UPLC-MS-based approach
por: Cheng, Xiaohong, et al.
Publicado: (2023)

Untargeted metabolomics reveals dynamic changes in metabolic profiles of rat supraspinatus tendon at three different time points after diabetes induction
por: Xu, Kuishuai, et al.
Publicado: (2023)

New therapeutic directions in type II diabetes and its complications: mitochondrial dynamics
por: Wang, Shengnan, et al.
Publicado: (2023)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Differential Lipidomic Characteristics of Children Born to Women with Polycystic Ovary Syndrome
por: Zhang, Zhirong, et al.
Publicado: (2021)

Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes
por: Zhang, Yaqin, et al.
Publicado: (2021)

Exosomes: Biomarkers and Therapeutic Targets of Diabetic Vascular Complications
por: Chen, Anqi, et al.
Publicado: (2021)

The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
por: Raman, Vandana S., et al.
Publicado: (2010)

Potential therapeutic role of pyroptosis mediated by the NLRP3 inflammasome in type 2 diabetes and its complications
por: Li, Xiang, et al.
Publicado: (2022)

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018)

Plasma Metabolomics Reveals Metabolic Profiling For Diabetic Retinopathy and Disease Progression
por: Sun, Yu, et al.
Publicado: (2021)

Proteomic profiling and correlations with clinical features reveal biomarkers indicative of diabetic retinopathy with diabetic kidney disease
por: Fan, Xiao’e, et al.
Publicado: (2022)

Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women
por: Rodgers, Megan, et al.
Publicado: (2021)

Gut microbiota profiling revealed the regulating effects of salidroside on iron metabolism in diabetic mice
por: Shi, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d5784uct48c3aeu0ttq1gpes4p